
According to Apellis and Sobi, pegcetacoplan (Aspaveli) first received marketing authorisation for treatment of paroxysmal nocturnal hemoglobinuria.

According to Apellis and Sobi, pegcetacoplan (Aspaveli) first received marketing authorisation for treatment of paroxysmal nocturnal hemoglobinuria.

The UK-based company will debut the tool, called Dr.Noon CVD, at two conferences in March.

Patients who underwent bilateral treatment experienced a higher rate of clinically relevant recovery, the authors reported.

The University of Bristol research team used animal models to compare patient responses to AAV therapy, studying male and female eye cells across different age groups (young, middle-aged and older patients)

The two products, both manufactured by Amgen, are aflibercept biosimilars Pavblu and Skojoy. Both biosimilars are indicated for treatment of AMD.

The gel addresses necrotic retinal cell death in dry age-related macular degeneration and geographic atrophy without requiring injections.

Previously, Teva was established as the European commercialisation partner of FYB201, Formycon's biosimilar to ranibizumab (Lucentis).

The additions to the ANTERION Cornea App will be commercially available in February 2025

ViGeneron also received approval for dose escalation in the ongoing phase 1b clinical trial.

Oxular began a phase 2 trial for its therapeutic candidate OXU-001, for the treatment of diabetic macular edema in October 2024.

The Danish Medicines Agency requested the EMA's Pharmacovigilance Risk Assessment Committee review reports on the vision-threatening condition.

Trending topics and milestone stories from our year in ophthalmology.

Glaucoma specialists discuss pairing patients with the right procedures.

Research data published earlier this year could help clinicians gain a better understanding of what to look for in a specular microscope, and how to interpret inter- and intradevice repeatability results in a way that benefits their existing practice framework.

The EMA issued a positive opinion and recommendation for marketing authorization for Eydenzelt (biosimilar aflibercept).

The joint project AMD-HALT, pairs Amarna’s SV40-derived gene delivery vector platform with Phenocell’s in vitro AMD disease model, which accurately mimics cellular interactions and microenvironment of the retina

Astellas said in a press release that the FDA comments in the CRL relate to proposed labeling language, not safety.

A coalition of eye health advocacy groups vocalized support for the legislation

Analysis highlights discrepancies between adult, pediatric cataract procedures.

Victoria L Tseng, MD, PhD, assistant professor of ophthalmology and a glaucoma specialist at UCLA and scientist at Doheny Eye Institute, spoke with the Eye Care Network at this year's AAO meeting about the "Glaucoma Original Papers" session and discussed the papers presented in the session by Giovanni Montesano, MD; Jason D Horowitz, MD; Christopher M Edwards, BS; Eamonn Thomas Fahy, BMBCH; Kiana Tavakoli, MD; Hani El Helwe, MD; and Joseph F Panarelli, MD.

At the American Academy of Ophthalmology (AAO) meeting in Chicago, Illinois, Brent Kramer, MD, he talked with the Eye Care Network about using the MKO Melt in lieu of IV anaesthesia ahead of ocular surgery.

The DOG recognised Heidelberg Engineering founder Christoph Schoess, Prof Herbert Kaufmann, and Prof Ioannis G. Pallikaris

The Eye Care Network adds a longstanding, CME-certified to its live event programming.

The IOL, designed with artificial intelligence, will launch at this year's ESCRS Congress in Barcelona, Spain

Outgoing National Medical Association ophthalmology section chair Fasika Woreta, MD, discussed the Roman-Barnes Distinguished Lecture ahead of the NMA meeting.

Carl C Awh, MD, FASRS, sat down with Hattie Hayes, Editor of Ophthalmology Times Europe, to discuss the first readout of the Phase 3 PAGODA trial at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

Martin Zinkernagel, MD, PhD, sat down with Hattie Hayes, Editor of Ophthalmology Times Europe, to discuss his time on the sustainability expert panel Study at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

The award, supported by Oculis, will recognize outstanding contributions to retina research and will grant €30,000 for research support, and an additional €5,000 directly to the candidate.

The agency approved Yesafili (Biocon Biologics) and Opuviz (Samsung Bioepis, Biogen) as biosimilars to Eylea (Regeneron Pharmaceuticals).

Antonio Filipe Macedo, OD, MSc, PhD, sat down to discuss his presentation at this year's ARVO meeting held in Seattle, Washington, about vision-related activity difficulties in people diagnosed with neovascular age-related macular degeneration (nAMD)and vision impairment.